Zimmer Holdings is a global leader in the development and manufacture of orthopaedic implants and related products, focusing on enhancing the quality of life for individuals suffering from conditions related to bones and joints. The company specializes in a wide range of surgical products and services, including joint replacement systems, trauma products, and a variety of surgical instruments. Zimmer Holdings also invests in innovative technologies and solutions to improve surgical outcomes and patient satisfaction, catering to healthcare professionals and institutions worldwide. With a commitment to advancing orthopaedic care, the company plays a crucial role in both the medical community and patient rehabilitation processes. Read More
BALA CYNWYD, Pa., July 14, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Zimmer Biomet plans to acquire Monogram and integrate its robotic knee system into its ROSA platform to support growth and product expansion through 2027.
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,
and over the past six months, the industry has pulled back by 6.3%. This drop is a far cry from the S&P 500’s 6.2% ascent.
ZIMMER BIOMET HOLDINGS INC (NYSE:ZBH) offers a reliable dividend with strong profitability and reasonable valuation, making it a candidate for income investors.
While profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
ZIMMER BIOMET (NYSE:ZBH) is an undervalued medical device stock with strong profitability, a reasonable dividend, and improving growth prospects. A solid pick for value investors.
Hitting a new 52-week low can be a pivotal moment for any stock.
These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds.
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets.
But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.
Zimmer Biomet Holdings (NYSE:ZBH) offers a reliable dividend with strong profitability and reasonable valuation, making it a solid pick for income investors.
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner.
Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.
PONTE VEDRA, Fla., June 05, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® procedures, today announced that it filed a lawsuit against Zimmer Biomet Holdings, Inc. and Paragon 28, Inc. (collectively, “Zimmer”) (NYSE: ZBH), alleging infringement of 4 patents related to Treace’s innovative Lapiplasty® 3D Bunion Correction® technologies. The suit was filed in the United States District Court for the District of Delaware, and seeks injunctive relief and damages.
ZIMMER BIOMET HOLDINGS (NYSE:ZBH) is an undervalued medical device stock with strong profitability, reasonable debt, and improving growth prospects, making it a candidate for value investors.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how surgical equipment & consumables - diversified stocks fared in Q1, starting with Zimmer Biomet (NYSE:ZBH).
Zimmer Biomet Holdings (NYSE:ZBH) offers a reliable dividend with strong profitability and decent financial health, making it a candidate for income investors.
Medical device company Zimmer Biomet (NYSE:ZBH) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 1.1% year on year to $1.91 billion. Its non-GAAP profit of $1.81 per share was 2.3% above analysts’ consensus estimates.
ZIMMER BIOMET HOLDINGS INC has a stellar value proposition. NYSE:ZBH not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point.
